PUBLIC COMPANY
save$RCKTROCKET PHARMACEUTICALS, INC.
$RCKTNew York, NY, USupdated 2mo ago
community read0 votes
pipeline
4
marketed
1
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(4)
pipeline depth4 products
2Phase 11Phase 21Marketed
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease
- phase2Clinical Trial to Evaluate the Efficacy of Gene Therapy for Pyruvate Kinase Deficiency
- phase1A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM)
- —Long-Term Follow-up: Phase I/II Clinical Study to Evaluate the Safety and Efficacy of the Infusion of RP-L102
- —Long-Term Follow-up of Subjects With Fanconi Anaemia Subtype A Treated With ex Vivo Gene Therapy
- —Danon Disease Natural History Study
- phase1A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy
- —BAG3-DCM Natural History Study
🐶 Hiring Signal
News
- Rocket's PRV goes for $180M; Oruka targets $500M offeringRocket sells PRV for $180M: The New Jersey gene therapy maker sold the rare pediatric disease priority review voucher to an undisclosed buyer. Rocket Pharmaceuticals got the PRV after securing FDA ...endpoints · 5mo ago
Data sources
last refreshed 44m ago
Found something off?
comments(0)
5-min edit window · permanent after that